According to a survey from Northern Italy in 7371 dialysis patients (378) it was 5.5% in all patients together but increased with duration of RRT, from 9.2% after 10-15 years to 20.8% after 16-20 years of dialysis therapy
The standard dose of PEA for humans ranges from 300 mg to 600 mg taken twice daily (total daily dose of 600 mg to 1,200 mg)
According to a report by the South Carolina Daily Gazette, Medicaid spending on GLP-1 drugs like Ozempic increased from $597.3 million in 2019 to $3.9 billion in 2023
The average participant was 44 years old, weighed about 249 pounds (113 kg), and had been living with obesity for an average of 16 years.[1] The study was funded by Eli Lilly, the maker of tirzepatide
Gut and systemic GLP-1 resistance have been previously described in HFD-fed mice, associated with dysglycemia, insulin resistance, increased food intake, and impaired gastric emptying, and attributed to an acquired impairment of the gut-brain axis secondary to intestinal dysbiosis (34)